DexCom Earnings & Forecasts

DexCom (DXCM) earnings history, EPS estimates, revenue forecasts and company guidance.

DexCom Guidance

DexCom (DXCM) は、7 30, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$5.18B - $5.25Bの範囲と予想しています。

以前のガイダンスと比較して、DexComは売上高予測を以前の範囲である維持から$5.16B - $5.25Bに引き上げました。

DexComは、29から10 27, 2022の間に7 30, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 7 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$0.67	$0.73	$0.63	$0.75
Revenue
Consensus	$1.33B	$1.40B	—	—

Earnings & Guidance News

SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today

SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.

Piero Cingari

PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.

Benzinga Newsdesk

PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same

Benzinga Newsdesk

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback

Vandana Singh

PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following

Benzinga Newsdesk

PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period

Benzinga Newsdesk

DexCom Inc

ニュース

パートナーシップ

ベンジンガ・グローバル